Evidence map›Paper›PMID 42699890›Full record

ArticleInternational journal of surgery case reports2026

Multicentric metachronous giant cell tumor of the femur: a rare case report and review of the literature.

Christopher Paul, Jimmy Olomi

Abstract readCase Reports
In one paragraph

Article in International journal of surgery case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Christopher PaulDepartment of Orthopedics and Trauma, Consolata Ikonda hospital, Njombe, Tanzania.
Jimmy OlomiDepartment of Orthopedics and Trauma, Mbeya College of Health and Allied Sciences, University of Dar es Salaam, Mbeya, Tanzania.ORCID https://orcid.org/0009-0007-2245-9364

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Giant cell tumor of bone (GCTB) is a benign but locally aggressive osteolytic neoplasm that most commonly presents as a solitary lesion in long bones. Multicentric GCTB is rare, comprising fewer than 1% of all cases, and metachronous involvement of two distinct regions within the same bone is exceptionally uncommon. Case presentation: We report the case of a 22-year-old man who initially presented with a 2-year history of right knee pain. Radiologic and histopathologic evaluation confirmed a Campanacci grade III GCTB of the distal femur, which was treated with intralesional curettage, polymethylmethacrylate augmentation, and adjuvant radiotherapy. Seven months later, he developed new-onset right hip pain. Imaging revealed a separate osteolytic lesion of the proximal femur. Histopathology confirmed a second GCTB lesion, establishing the diagnosis of multicentric metachronous disease. Clinical discussion: The development of a second histologically confirmed GCTB within the same femur shortly after treatment of the primary lesion represents a rare diagnostic and therapeutic challenge. Distinguishing metachronous multicentric disease from intramedullary skip lesions and metastatic or metabolic bone disease is critical, as management and prognosis differ substantially. The recommended treatment for GCTB is curettage, but this may not be possible when the lesion is located in the proximal femur. Conclusion: This case highlights an exceptionally rare presentation of a metachronous, multicentric GCTB occurring in different regions of the same long bone. Vigilant long-term radiologic surveillance is essential.

Indexed as

bone neoplasmcase reportfemurgiant cell tumor of bonemetachronous lesionsmulticentric GCTB

Identifiers

PMID42699890
PMCPMC13544778

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.